Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )

NCT01569295 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

416

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG: Idelalisib
DRUG: Rituximab
DRUG: Bendamustine
DRUG: Placebo to match idelalisib

Sponsor

Gilead Sciences